PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Both yoy net incomes decline, with TRAW at -9.01%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.01%
Less D&A growth vs. TRAW's 33.33%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
9.00%
SBC growth of 9.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
715.46%
Slight usage while TRAW is negative at -60.59%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
A yoy AP increase while TRAW is negative at -438.75%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
304.81%
Growth well above TRAW's 323.83%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
412.12%
Lower 'other non-cash' growth vs. TRAW's 1796.74%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
9.59%
Operating cash flow growth above 1.5x TRAW's 0.05%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
100.00%
CapEx growth of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-4.76%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-85.80%
Both yoy lines negative, with TRAW at -100.25%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.